Colorado stock (MA0000011934): Trading at low levels amid medical device focus

Colorado, a medical device firm specializing in electrotherapy for pain management, trades at $0.06 per share with a market cap of $1.67 million as of May 12, 2026.

Colorado stock (ticker ZYXIQ) recently traded at $0.06, reflecting a market capitalization of $1.67 million, according to Robinhood as of 05/12/2026. The company, which engages in designing, manufacturing, and marketing electrotherapy devices for pain management and rehabilitation, shows a P/E ratio of -0.02. This price level highlights its position in the competitive medical device sector, relevant for US investors tracking small-cap healthcare plays on US exchanges.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Zynex, Inc. (Colorado)
• Sector/industry: Medical devices
• Headquarters/country: United States
• Core markets: Pain management and rehabilitation
• Home exchange/listing venue: OTC (ZYXIQ)
• Trading currency: USD

Colorado: core business model

Colorado, operating as Zynex, Inc., focuses on non-invasive medical devices for pain management and rehabilitation. The company designs and markets electrotherapy products that help patients recover from injuries or manage chronic pain without surgery or drugs. This model targets healthcare providers and direct-to-consumer channels in the US market.

Key to its operations is a portfolio of FDA-cleared devices used in clinical settings, physical therapy, and home care. With exposure to the growing US demand for outpatient rehabilitation, Colorado serves a niche appealing to investors interested in healthcare innovation amid aging demographics.

Main revenue and product drivers for Colorado

Revenue primarily stems from sales of electrotherapy devices like TENS units and muscle stimulators. These products address post-surgical pain, sports injuries, and neurological conditions, with distribution through medical supply channels and online platforms. The US represents a core market, where reimbursement dynamics influence growth.

Product innovation drives expansion, including portable devices for home use. Recent trading levels at $0.06 on May 12, 2026, underscore valuation pressures, yet the sector's resilience offers context for US investors monitoring small-cap medtech.

Industry trends and competitive position

The electrotherapy market benefits from rising demand for non-opioid pain relief in the US, fueled by the opioid crisis and preference for outpatient care. Competitors include larger players like DJO Global, but Colorado's focus on niche, affordable devices positions it for targeted growth.

Why Colorado matters for US investors

As an OTC-listed stock, Colorado provides exposure to US healthcare spending, which exceeds $4 trillion annually. Its low market cap of $1.67M as of May 12, 2026, appeals to speculative investors seeking turnaround stories in medtech, with relevance to domestic rehabilitation needs.

Conclusion

Colorado remains a small player in electrotherapy with recent trading at $0.06 and a $1.67M market cap as of May 12, 2026. Its focus on pain management devices aligns with US healthcare trends, though low valuation reflects market challenges. Investors track such names for potential shifts in medtech demand.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.